Hsp90 N-terminal inhibitor 17-AAG and C-terminal inhibitor cisplatin synergistically eradicates Bcr-

来源 :2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会 | 被引量 : 0次 | 上传用户:q3356367
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Hsp90 is a ubiquitous molecular chaperone that regulates over 200 client proteins involved in multiple growth and signaling pathways,which are targets for chemotherapeutic strategies.Thus,Hsp90s role as a master regulator has made it an attractive candidate for drug development.Hsp90 exists.as a homodimer in the cytosol,with three highly conserved domains.Both amino(N-) and carboxyl(C-) terminal domains of Hsp90 interact to cochaperones or ATP and then modulate chaperone activity.
其他文献
目的:探讨清洁间断自家导尿术在神经原性膀胱排空障碍中的作用。方法:确诊的9例神经原膀胱患者,指导其自家清洁间歇导尿,每月定期随访尿常规和尿培养。结果:9例均获随访,均能掌握自家清洁间歇导尿术。结论:长期临床观察证实CIC有良好的安全性、有效性和耐受性。而且CIC也易于被患者或其家属掌握。只要进行适当的随访,CIC技术的普及将明显提高膀胱尿道功能障碍患者的生存期和生活质量。
目的:探讨机器人辅助腹腔镜前列腺癌根治术的临床应用。方法:回顾性分析Hartford医院2003年12月-2007年2月560例机器人辅助腹腔镜前列腺癌根治术的临床资料.结果:其中T2期占72%,T3期25%,N1期3%,术前PSA平均5.6ng/ml,手术平均耗时191分钟,术中平均出血260ml,住院时间1.8天,只有2.2%的患者术后PSA复发,高风险及中低风险切缘阳性率分别为48%和29%
目的:探讨糖尿病对良性前列腺增生(BPH)患者膀胱功能改变的影响。方法:回顾性分析166例前列腺增生患者的资料,根据是否合并糖尿病将患者分为研究组和对照组,比较两组临床资料和尿动力学检查结果之间关系。结果:研究组患者中的残余尿量显著高于对照组(P<0.05);研究组中最大膀胱压测定容积(MCC)、膀胱顺应值(BC)、膀胱感觉功能受损比例和膀胱过度活动症比例(OAB)明显高于对照组;排尿期最大逼尿肌
Objectives To assess the role of Color Doppler Flow Imaging (CDFI) in the evaluation of Chinese patients with erectile dysfunction (ED) and to explore the association between penile rigidity and hemo-
会议
Objective:To investigate a reasonable pattern of goal diagnosis and therapy for male erectile dysfunction.Materials and methods:196male patients suffered with erectile dysfunction were accepted and di
会议
Dicycloplatin,a new supramolecular platinum antitumor drug which was formed by one molecule carboplatin and one molecule 1,1-ring succinic acid via the effect of hydrogen bond.In this study,we investi
Imidazopyridine CCT129202 is an inhibitor of Aurora kinase activity and displays favorable antineoplastic effect in preclinical studies.Here,we investigated the enhanced effect of CCT129202 on the cyt
Purpose:The "gate-keeper" mutations T6741 PDGFRα in hypereosinophilic syndrome (HES) and T3151 Bcr-Abl in chronic myeloid leukemia (CML),are resistant to imatinib and the second-generation small molec
会议
Limited treatment options are available for chronic myeloid leukemia (CML) patients who develop imatinib mesylate resistance particularly in patients with gatekeep mutant Bcr-Abl such as T3151.Compoun
会议
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML),but resistance attributable to kinase domain mutations can lead to relapse.Mutation of
会议